Dataset Information
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope.
Ontology highlight
ABSTRACT: Purpose of review
Systemic sclerosis (SSc) is an autoimmune connective tissue disease in which there is an activation of fibroblast to a myofibroblast that secretes huge amounts of extracellular matrix. Currently, no treatment exists that modifies the fibrosis elements and new therapeutic targets are badly needed. This review examines the current state of treatments and emerging therapeutics.Recent findings
Nintedanib was found to significantly reduce the rate of decline in SSc associated FVC, although it has no benefit on skin fibrosis. New cannabinoid receptor2 agonist has shown superb effects in phase II and results in phase III are anticipated. Other targets are currently being tested in clinical trials and new targets that are yet to be tested are increasing in the SSc literature. Nintedanib is now licenced for SSc interstitial lung disease but this does not modify the skin fibrosis. Current ongoing trials will determine the role of various targets. New targets are emerging as we gain a deeper understanding of disease pathogenesis.
SUBMITTER: Hinchcliff M
PROVIDER: S-EPMC7305248 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Publications
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope.
Current rheumatology reports 20200619 8
<h4>Purpose of review</h4>Systemic sclerosis (SSc) is an autoimmune connective tissue disease in which there is an activation of fibroblast to a myofibroblast that secretes huge amounts of extracellular matrix. Currently, no treatment exists that modifies the fibrosis elements and new therapeutic targets are badly needed. This review examines the current state of treatments and emerging therapeutics.<h4>Recent findings</h4>Nintedanib was found to significantly reduce the rate of decline in SSc a ...[more]